These studies suggest that crizotinib-resistant tumors keep dependency on ALK signaling, and this is extremely interesting since both ceritinib and alectinib are able to inhibit ALK-positive NSCLC mutants harboring different resistance mutations [60]. Here, ALK is linked to non-small cell lung carcinoma.